

University of Massachusetts Medical School

eScholarship@UMMS

UMass Center for Clinical and Translational
Science Research Retreat

2014 UMass Center for Clinical and
Translational Science Research Retreat

May 20th, 2:30 PM

Optimizing the Exercise Drug to Oppose Glucose Intolerance/T2D

Barry Braun

University of Massachusetts Amherst

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat



Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, Endocrinology, Diabetes, and Metabolism Commons, Exercise Science Commons, Nutritional and Metabolic Diseases Commons, and the Translational Medical Research Commons

Braun B. (2014). Optimizing the Exercise Drug to Oppose Glucose Intolerance/T2D. UMass Center for Clinical and Translational Science Research Retreat. Retrieved from https://escholarship.umassmed.edu/cts_retreat/2014/presentations/3

Creative Commons License



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/).

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

Optimizing the Exercise Drug to Oppose Glucose Intolerance/T2D




Barry Braun, PhD
Dept. of Kinesiology
University of Massachusetts Amherst



Lab mission: Metabolic rehabilitation

Understand how physical activity, diet and pharmacology can be optimally integrated to reverse insulin resistance and prevent T2D






79 million with prediabetes=

everyone in U.S. that is left-handed (30) +
everyone who is Jewish (6) +
all households in U.S. that own dogs (43).


Insulin resistance is an underlying theme for
Type-2 diabetes (as well as CVD)



Insulin Resistance



Diabetes Prevention Program, NEJM, 2001



>150' exercise/wk. goal to lose 7% BW.



Lifestyle change



Metformin



Weight loss


beneficial impact on metabolic health




Mean weight loss: 3.3 kg

Activity maintained at about 150'/wk

A



B



C



Lifestyle change



habitual activity

Metformin




Weight loss

beneficial impact on metabolic health



Single dose



King et al., JAP, 1995



Lifestyle change




Weight loss

exercise training



acute exercise



Metformin



beneficial impact on metabolic health



Exercise as drug

At sufficient **dose**, exercise improves metabolic function for a period of time but the effect wanes, requiring subsequent doses.

Tailoring dose to achieve maximal effect is likely to result in biggest long-term reward



What do we need to know?

Dose:

Threshold (\approx 150 min/week)

Frequency (3+ d/wk)

Intensity/Duration (HIIT, sedentary time?)

Interactions with diet


Interactions with other medications



No-Exercise

LO = 3 bouts at 50%
 $VO_2max, = 750$ kcal


HI = 3 bouts at 75%
 $VO_2max, = 750$ kcal



Braun et al. J Appl. Physiol. 1995



Interactions with diet: Energy balance?




	DEF	BAL
Energy Ingested (kcal)	2246 ± 97	2925 ± 159
Estimated Energy Expenditure (kcal)	2727 ± 182	2917 ± 169
Energy Balance (kcal)	-481 ± 24	+8 ± 20
Weight Change (kg)	-0.62 ± 0.2	+0.03 ± 0.2

All food provided, EE derived from RMR, accelerometers, food, activity records




Whole-body and hepatic insulin action (CIG-SIT)




Outcomes: whole-body glucose uptake and suppression of liver glucose output





Black et al. J Appl Physiol, 2005



Energy balance the only difference?

CHO content of diets in 2 groups different.

DEF = 330 g CHO/day; BAL = 410g/day.

Meal (60% CHO) **immediately** post-exercise





Lifestyle change

Pharmacology




Weight loss

exercise training



acute exercise




timing

meal CHO




energy balance

beneficial impact on metabolic health



Diabetes Prevention Program, NEJM, 2001



Lifestyle + metformin = even better?



Exercise and metformin




Purpose: Combined effect of metformin and acute exercise on insulin sensitivity and AMPK α 2

Hypothesis: 1 + 1 = 2



**Metformin group:
pre-Met, Met + rest, post Met + Ex**

**Placebo group:
rest, exercise**





Percutaneous biopsy of vastus lateralis

Blood sampling

Goodyear lab for analyses of AMPK activity, glycogen, and western blots.







Does metformin blunt beneficial effects of training?




32 men and women with prediabetes

12 wks training with or w/o metformin, metformin only and control

Insulin sensitivity using clamp and tracers





Insulin sensitivity enhanced more with exercise alone than when combined with metformin



Non glyceemic outcomes

SBP:

C= +6.5%, M= -7.3%, EP= -6.3%, EM= 0.0%

hs-CRP:

C= +6.4%, M= -20.1%, EP= -27.4%, EM=-8.4%

TAG:

C= +3.1% M= -13.8%, EP= -13.5%, EM= -12.0%



Why?

Wt? Only M and E+M lost weight

Fat? M = nc, E+M and E+P= -2%

Central fat? M= nc, E+M and E+P= -1.5%

CRF? M = nc, E+M \approx +10%, E+P \approx +20%

$\Delta\text{VO}_2\text{peak}$ and $\Delta\text{insulin sensitivity}$: $r = .70$





Lifestyle change

metformin




Weight loss

exercise training



acute exercise



timing

meal CHO




energy balance

beneficial impact on metabolic health



Role of “sedentary behavior” in mediating efficacy of the exercise drug??



14 normally active men and women
 3 conditions, balanced order



Active, energy bal (no sit 15 hr.)





Inactive (sit 15 hr, no diet change)



Inactive, (sit 15 hr, cut kcals)








Sedentary subjects

Control, 12 wks training (EX), reduced sedentary time (rST) OR both (EX+rST).

EX+rST accentuated impact of EX alone
C-ISI up by 24% vs. 17.5% (but TG same)

Little impact of rST alone





Conclusions




At sufficient dose, exercise/physical activity
potent countermeasure

Less sedentary behavior useful but not sufficient

Interxns between exercise and nutritional context

Interactions with other meds NOT predictable





beneficial impact on metabolic health



Tara D'Eon, PhD
Steve Black PhD
Carrie Sharoff PhD
Brooke Stephens PhD
Kaila Holtz MS
Todd Hagobian PhD
Rebecca Hasson PhD
Steve Malin, PhD
Rob Gerber MS
Kirsten Thomson MS
Cameron Carter, MS
Rich Viskochil MS
Jen Blankenship, MS
Hannah Masse, BS
Patty Freedson, PhD
Stuart Chipkin MD
Laurie Goodyear PhD
John Staudenmayer PhD
Sarah Kozey Keadle, PhD
Kate Lyden, PhD



NIH 5 R56 DK081038
American Diabetes Assoc. 7-04-JF-10
Glass Charitable Trust
Baystate/UMass CBRP
ACSM Student grants

